Trial Profile
A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Inebilizumab (Primary) ; Carboplatin; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Ifosfamide; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors MedImmune
- 04 Aug 2016 Status changed from active, no longer recruiting to completed.
- 20 Jul 2016 This trial is discontinued in Czech Republic according to European Clinical Trials Database record.
- 30 Jun 2016 This trial is discontinued in Germany ( End date: 17 Jun 2016) and suspended in Italy.